Bob Mittleman, MD, MS, FACC



  • Board-certified cardiologist with 17 years of experience in clinical development, and more than 10 years on the faculty of a major medical school with clinical, clinical research, teaching, and administrative duties.

Clinical Development, Clinical Trials Design / Plan (Phases 1-4), Medical Monitoring, Investigator Meetings and Site Interactions, CRO Management, Documents, Review / Synthesis of Trial Results, FDA Interactions (all phases of development), Due Diligence, In-licensing / Out-licensing, Partnering Initiatives, Presentations, and Leadership. Therapeutic Areas: Cardiovascular, Rare Disease, Gastroenterology, and Hematology.
Authored/co-authored more than 40 peer-reviewed manuscripts, book chapters, and reviews; principle/co-investigator on 40 different industry and NIH-funded research trials.
MD, Medical College of PA (Drexel); MS, Pharmacology, Emory University; BA, Chemistry, Cornell University.
Principal Consultant, Mittleman Consulting, LLC
Consults on clinical development for pharmaceutical and medical devices.
Senior Medical Director, Ironwood Pharmaceuticals
As Medical Lead, proposed a Phase 2 study for the evaluation of a novel sGC stimulator for the treatment of heart failure; developed the full protocol, led an Advisory Board, and executed the trial. Medical Lead for a Phase 2 study for the treatment of pGERD for study execution and interpretation and presentation of results to senior management and partner KOLs. Proposed Phase 3 trial design and led an Advisory Board and FDA interactions at end-of-Phase 2. Filed an IND for a different sGC stimulator, including design, conduct, and interpretation of two Phase 1 studies, and design for Phase 2 studies in two indications targeting rare diseases (sickle cell disease and achalasia). Participated in due diligence teams for the evaluation of multiple drugs for potential in-licensing and partnering opportunities, as well as for potential out-licensing/partnering for an investigational drug with multiple potential indications.
Senior Medical Director, Genzyme, (a Sanofi Company)
Medical Lead for clinical development of a form of small interfering RNA (si RNA) to treat familial amyloid cardiomyopathy, including the development of a Phase 3 protocol and interaction with European and US regulatory agencies, resulting in an approved clinical trial design. Collaborated to refine global development plan. Participated in due diligence team evaluating a large collaborative agreement between Genzyme and Alnylam, including review of multiple drugs in preclinical and clinical development, culminating in an investment of over $500 million and resulting in multiple new development projects for Genzyme. Medical Lead for execution and development of multiple clinical protocols supporting the EMA/NDA/sNDA process for a novel anti-sense lipid-lowering medication, including protocol development, interaction with KOLs, presentations for senior management, preparation of study documents, and review and interpretation of data.
Senior Medical Director, I3Global/I3Research (a division of United Health Group)
Led cardiovascular/scientific input to large (>$100 million) proposals to pharmaceutical companies for Phase 2/3/4 research studies. Part of proposal team for a large multinational study resulting in award of a $30,000,000 contract; served as therapeutic advisor for project, with multiple protocol-related responsibilities. Performed medical monitoring activities and developed and executed cardiovascular therapeutic area training for Medical & Scientific Affairs, operational, and other staff.
Associate Medical Director, Bristol-Meyers Squibb Medical Imaging
Medical/scientific leadership for clinical development program for a pharmacologic stress agent involving nine separate Phase 1-3 clinical trials, including Phase 3 trials, a pharmacokinetics study, and a special population study. Medical monitor for two large studies for the leading cardiac nuclear imaging agent (Cardiolite). Collaborated on a clinical development plan for a new cardiac imaging agent, including writing a protocol for a first-in-man study.

Join Today

Curabitur arcu erat, accumsan id imperdiet et, porttitor at sem. Cras ultricies ligula sed dictum porta. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur non nulla sit amet nisl tempus convallis quis ac lectus. Curabitur arcu erat, accumsan id imperdiet et